Skip to main content

Table 2 Baseline patient characteristics

From: Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials

  Celecoxib
(n= 28,614)
nsNSAID
(n= 15,278)
Placebo
(n= 5,827)
Rofecoxib
(n= 1,329)
Total
(n= 51,048)
Age, years      
   Mean, SD 60.1 (13) 59.3 (13) 57.2 (14) 70.6 (9) 59.8 (13)
   ≥ 65 years, n (%) 11,404 (40) 5,667 (37) 1,901 (33) 1,115 (84) 20,087 (39)
   ≥ 75 years, n (%) 3,421 (12) 1,656 (11) 513 (9) 460 (35) 6,050 (12)
Female, n (%) 18,819 (66) 10,478 (69) 3,251 (56) 860 (65) 33,408 (65)
Indication      
   OA/RA, n (%) 23,324 (82) 13,911 (91) 3,074 (53) 1,329 (100) 41,638 (82)
Low-back pain, n (%) 1,743 (6) 850 (6) 1,042 (18) 0 (0) 3,635 (7)
Ankylosing spondylitis, n (%) 895 (3) 517 (3) 232 (4) 0 (0) 1,644 (3)
   Alzheimer disease, n (%) 329 (1) 0 (0) 158 (3) 0 (0) 487 (1)
   Oncology, n (%) 2,323 (8) 0 (0) 1,321 (23) 0 (0) 3,644 (7)
Duration, n (%)      
≤ 12 weeks 15,597 (55) 8,322 (55) 3,871 (66) 1,245 (94) 29,035 (57)
> 12 and ≤ 26 weeks 7,878 (28) 4,271 (28) 675 (12) 84 (6) 12,908 (25)
> 26 and ≤ 52 weeks 2,307 (8) 1,958 (13) 90 (2) 0 (0) 4,355 (9)
≥ 52 weeks 2,832 (10) 727 (5) 1,191 (20) 0 (0) 4,750 (9)
Total patient-years of exposure 12,276.3 4,621.8 3,755.6 154.5 20,808.2
100 patient-years of exposure 122.8 46.2 37.6 1.6 208.1
  1. 100 Patient-years of exposure = total patient-years of exposure divided by 100. nsNSAID, nonselective nonsteroidal antiinflammatory drug; OA, osteoarthritis; RA, rheumatoid arthritis.